BSX
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Boston Scientific Corporation
- Nom
- Boston Scientific Corporation
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NYSE
- Capitalisation
- $66.2B
- Employés
- 59,000
- PDG
- Michael F. Mahoney
- Site web
- https://www.bostonscientific.com
- Marché
- ANGOATRCCNMDCVRXEWLIVN
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 196 562 titres (~9 486 038,29 $ US)
- Insiders
- Morano Susan EHabiger David CMahoney Michael FLUDWIG EDWARD J
- Total bought
-
$9,486,038
Avg buy (VWAP, 90d window) $48.26 vs last close $45.58 (-5.6%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-25
- Liquidity
- Liquid $684,701,158/day · 20d vol
- Last synced
-
2026-10-27 02:52:58
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-25 | Morano Susan E | Buy · P | 2,040 | $49.22 | $100,408 | Form 4 |
| 2026-08-05 | Habiger David C | Buy · P | 2,100 | $47.59 | $99,937 | Form 4 |
| 2026-08-04 | Habiger David C | Buy · P | 140 | $48.59 | $6,802 | Form 4 |
| 2026-08-03 | Habiger David C | Buy · P | 1,042 | $48.07 | $50,084 | Form 4 |
| 2026-08-03 | Mahoney Michael F | Buy · P | 186,240 | $48.33 | $9,001,408 | Form 4 |
| 2026-07-31 | LUDWIG EDWARD J | Buy · P | 5,000 | $45.48 | $227,400 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-18 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
| 2026-08-10 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-11 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-09-09 | Kevin Hern | Sale (Full) | $50,001 - $100,000 |
| 2026-09-04 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-09-04 | Kevin Hern | Sale (Partial) | $50,001 - $100,000 |
| 2026-09-03 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2026-09-03 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2026-09-03 | Kevin Hern | Sale (Full) | $1,001 - $15,000 |
| 2026-08-31 | Kevin Hern | Sale (Full) | $15,001 - $50,000 |
| 2026-08-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-08-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-07-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-06-05 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2026-06-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-06-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-05-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-05-19 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-05-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-30 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-03-27 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2026-02-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-01-30 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-31 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-10-30 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-10-28 | Kevin Hern | Sale | $15,001 - $50,000 |
| 2025-10-17 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-31 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-06-26 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-06-11 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-13 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-28 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-03-17 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2024-12-11 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-04 | John R. Curtis | Sale (Full) | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2023-10-31 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-10-31 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2023-10-31 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-10-27 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-10-27 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-10-18 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2023-10-18 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2023-10-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2023-05-31 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-05-30 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2023-05-01 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-26 | John R. Curtis | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-21 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-04-21 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-04-19 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-05 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-04-05 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2023-03-29 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-03-27 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-03-27 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2023-02-23 | John R. Curtis | Sale (Partial) | $1,001 - $15,000 |
| 2022-12-16 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-12-16 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-12-07 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-12-07 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-24 | Alan Lowenthal | Sale (Full) | $1,001 - $15,000 |
| 2022-10-21 | Alan Lowenthal | Sale (Partial) | $1,001 - $15,000 |
| 2022-10-21 | Alan Lowenthal | Sale (Partial) | $1,001 - $15,000 |
| 2022-09-28 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2022-09-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-06-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-05 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2022-05-05 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
| 2022-04-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-04-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-03-15 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-03-15 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-07 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2022-02-07 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-02-07 | Michael T. McCaul | Purchase | $1,001 - $15,000 |
| 2022-02-07 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2022-02-07 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2022-01-14 | Michael T. McCaul | Purchase | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
BSX exhibits strong financial health with solid liquidity (80) and improving fundamentals (85), supported by consistent margin expansion and robust cash flow generation.
The first sentence of the analysis written for BSX on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.62 · operating margin 20%
Suggested stop 43.79, nearest stored support minus 0.5 ATR(3.9% under the last close). Reward/risk to the next stored resistance is 0.09. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-26 Boston Scientific to participate in Stifel''s 2026 Healthcare Conference MARLBOROUGH, Mass., Oct. 26, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Stifel''s 2026 Healthcare Conference on Wednesday, November 11, 2026.
- 2026-10-23 Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics Besides Wall Street''s top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.
- 2026-10-23 Boston Scientific Corporation $BSX Stock Bought by Integrated Advisors Network LLC Integrated Advisors Network LLC boosted its holdings in Boston Scientific Corporation (NYSE: BSX) by 256.2% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,243 shares of the medical equipment provider''s stock after purchasing an additional 17,437 shares during the quarter. Integrated
- 2026-10-22 Boston Scientific: A Q3 Earnings Miss Likely Amid Product Recall, Cybersecurity Incident Boston Scientific remains a ''hold'' as growth decelerates and competitive pressures intensify, particularly in Watchman and electrophysiology segments. Management has shifted the growth focus to Interventional Cardiology, Endoscopy, and Neuromodulation, but meaningful improvements are not expected until 2028. Recent product recalls, a cybersecurity incident, and repeated guidance cuts further cloud near-term visibility and risk further downward revisions.
- 2026-10-22 BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation''s Directors and Officers for Breach of Fiduciary Duties -- BSX Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) f
- 2026-10-22 BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation''s Directors and Officers for Breach of Fiduciary Duties – BSX NEW YORK--(BUSINESS WIRE)---- $BSX #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On February 4, 2026, B.
- 2026-10-21 Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors Boston Scientific (BSX) closed at $44.51 in the latest trading session, marking a -2.35% move from the prior day.
- 2026-10-21 Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth Boston Scientific (BSX) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-10-21 BSX Set to Report Q3 Earnings: Will MedSurg Strength Aid Performance? Boston Scientific''s Q3 results hinge on MedSurg strength in Endoscopy and Neuromodulation, as Cardiovascular faces competitive pressures and softer sales.
- 2026-10-21 Boston Scientific Corporation $BSX Stake Raised by Louisbourg Investments Inc. Louisbourg Investments Inc. grew its holdings in Boston Scientific Corporation (NYSE: BSX) by 6.2% in the undefined quarter, according to the company in its most recent filing with the SEC. The firm owned 194,330 shares of the medical equipment provider''s stock after buying an additional 11,377 shares during the quarter. Boston Scientific makes
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.0% | 61.3% | 62.0% | 60.8% | 62.8% | |
| Ebit Margin | 18.6% | 15.9% | 15.8% | 12.7% | 12.0% | |
| Ebitda Margin | 25.4% | 23.5% | 24.2% | 21.6% | 21.2% | |
| Operating Profit Margin | 19.8% | 15.7% | 15.3% | 14.4% | 16.2% | |
| Pretax Profit Margin | 16.9% | 13.6% | 13.9% | 9.0% | 9.1% | |
| Continuous Operations Profit Margin | 14.4% | 11.0% | 11.2% | 5.5% | 8.7% | |
| Net Profit Margin | 14.4% | 11.1% | 11.2% | 5.5% | 8.7% | |
| Bottom Line Profit Margin | 14.4% | 11.1% | 11.0% | 5.1% | 8.3% | |
| Current Ratio | 1.617 | 1.081 | 1.320 | 1.515 | 1.478 | |
| Quick Ratio | 1.076 | 0.642 | 0.817 | 1.024 | 1.101 | |
| Solvency Ratio | 0.222 | 0.180 | 0.179 | 0.123 | 0.137 | |
| Cash Ratio | 0.376 | 0.065 | 0.175 | 0.244 | 0.450 | |
| Price To Earnings Ratio | 48.648 | 70.889 | 53.503 | 103.097 | 61.343 | |
| Price To Earnings Growth Ratio | 0.876 | 4.267 | 0.380 | -2.930 | -0.064 | |
| Forward Price To Earnings Growth Ratio | 0.876 | 4.267 | 0.380 | -2.930 | -0.064 | |
| Price To Earnings Diluted Ratio | 49.149 | 71.456 | 53.887 | 103.768 | 61.834 | |
| Price To Earnings Diluted Growth Ratio | 0.890 | 4.326 | 0.383 | -2.957 | -0.065 | |
| Price To Book Ratio | 5.825 | 6.037 | 4.356 | 3.766 | 3.635 | |
| Price To Sales Ratio | 7.032 | 7.848 | 5.899 | 5.219 | 5.082 | |
| Price To Free Cash Flow Ratio | 38.588 | 49.692 | 49.324 | 72.417 | 45.911 | |
| Price To Operating Cash Flow Ratio | 31.133 | 38.263 | 33.559 | 43.374 | 32.310 | |
| Debt To Assets Ratio | 0.284 | 0.283 | 0.270 | 0.286 | 0.293 | |
| Debt To Equity Ratio | 0.512 | 0.512 | 0.492 | 0.528 | 0.569 | |
| Debt To Capital Ratio | 0.339 | 0.339 | 0.330 | 0.346 | 0.362 | |
| Long Term Debt To Capital Ratio | 0.321 | 0.289 | 0.308 | 0.336 | 0.346 | |
| Financial Leverage Ratio | 1.802 | 1.810 | 1.822 | 1.848 | 1.939 | |
| Working Capital Turnover Ratio | 10.358 | 15.934 | 8.050 | 6.341 | 4.703 | |
| Operating Cash Flow Ratio | 0.834 | 0.537 | 0.507 | 0.401 | 0.438 | |
| Operating Cash Flow Sales Ratio | 0.226 | 0.205 | 0.176 | 0.120 | 0.157 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.807 | 0.770 | 0.680 | 0.599 | 0.704 | |
| Debt Service Coverage Ratio | 6.245 | 1.618 | 3.811 | 4.748 | 4.069 | |
| Interest Coverage Ratio | 11.378 | 6.809 | 8.018 | 3.931 | 5.507 | |
| Short Term Operating Cash Flow Coverage Ratio | 11.656 | 1.932 | 4.714 | 76.300 | 7.165 | |
| Operating Cash Flow Coverage Ratio | 0.365 | 0.308 | 0.264 | 0.164 | 0.198 | |
| Capital Expenditure Coverage Ratio | 5.176 | 4.348 | 3.129 | 2.493 | 3.375 | |
| Dividend Paid And Capex Coverage Ratio | 5.176 | 4.348 | 3.023 | 2.288 | 3.071 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.018 | 0.079 | 0.053 | |
| Enterprise Value Multiple | 29.700 | 36.101 | 26.824 | 27.196 | 26.984 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.0% | ▲7.7% | ▲5.8% |
| Ebit Margin | 18.6% | ▲2.7% | ▲3.6% |
| Ebitda Margin | 25.4% | ▲1.9% | ▲2.2% |
| Operating Profit Margin | 19.8% | ▲4.0% | ▲3.5% |
| Pretax Profit Margin | 16.9% | ▲3.2% | ▲4.4% |
| Continuous Operations Profit Margin | 14.4% | ▲3.4% | ▲4.2% |
| Net Profit Margin | 14.4% | ▲3.3% | ▲4.2% |
| Bottom Line Profit Margin | 14.4% | ▲3.3% | ▲4.4% |
| Current Ratio | 1.617 | ▲0.535 | ▲0.215 |
| Quick Ratio | 1.076 | ▲0.433 | ▲0.144 |
| Solvency Ratio | 0.222 | ▲0.042 | ▲0.054 |
| Cash Ratio | 0.376 | ▲0.311 | ▲0.114 |
| Price To Earnings Ratio | 48.648 | ▼-22.241 | ▼-18.848 |
| Price To Earnings Growth Ratio | 0.876 | ▼-3.392 | ▲0.370 |
| Forward Price To Earnings Growth Ratio | 0.876 | ▼-3.392 | ▲0.370 |
| Price To Earnings Diluted Ratio | 49.150 | ▼-22.306 | ▼-18.869 |
| Price To Earnings Diluted Growth Ratio | 0.890 | ▼-3.436 | ▲0.375 |
| Price To Book Ratio | 5.825 | ▼-0.212 | ▲1.101 |
| Price To Sales Ratio | 7.032 | ▼-0.816 | ▲0.816 |
| Price To Free Cash Flow Ratio | 38.588 | ▼-11.103 | ▼-12.598 |
| Price To Operating Cash Flow Ratio | 31.133 | ▼-7.130 | ▼-4.595 |
| Debt To Assets Ratio | 0.284 | ▲0.001 | ▲0.001 |
| Debt To Equity Ratio | 0.512 | ▲0.000 | ▼-0.010 |
| Debt To Capital Ratio | 0.339 | ▲0.000 | ▼-0.004 |
| Long Term Debt To Capital Ratio | 0.321 | ▲0.032 | ▲0.001 |
| Financial Leverage Ratio | 1.802 | ▼-0.007 | ▼-0.042 |
| Working Capital Turnover Ratio | 10.358 | ▼-5.576 | ▲1.281 |
| Operating Cash Flow Ratio | 0.834 | ▲0.297 | ▲0.290 |
| Operating Cash Flow Sales Ratio | 0.226 | ▲0.021 | ▲0.049 |
| Free Cash Flow Operating Cash Flow Ratio | 0.807 | ▲0.037 | ▲0.095 |
| Debt Service Coverage Ratio | 6.245 | ▲4.628 | ▲2.147 |
| Interest Coverage Ratio | 11.378 | ▲4.569 | ▲4.250 |
| Short Term Operating Cash Flow Coverage Ratio | 11.655 | ▲9.724 | ▼-8.698 |
| Operating Cash Flow Coverage Ratio | 0.365 | ▲0.057 | ▲0.105 |
| Capital Expenditure Coverage Ratio | 5.176 | ▲0.828 | ▲1.472 |
| Dividend Paid And Capex Coverage Ratio | 5.176 | ▲0.828 | ▲1.595 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▼-0.030 |
| Enterprise Value Multiple | 29.700 | ▼-6.402 | ▲0.339 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $141.16B | $131.43B | $84.00B | $66.19B | $60.42B | |
| Enterprise value | $151.53B | $142.17B | $92.62B | $74.54B | $67.95B | |
| EV / Sales | 7.55x | 8.49x | 6.50x | 5.88x | 5.71x | |
| EV / Op. cash flow | 33.42x | 41.39x | 37.01x | 48.85x | 36.33x | |
| EV / Free cash flow | 41.42x | 53.75x | 54.39x | 81.56x | 51.63x | |
| EV / EBITDA | 29.70x | 36.10x | 26.82x | 27.20x | 26.98x | |
| Net debt / EBITDA | 2.03x | 2.73x | 2.50x | 3.05x | 2.99x | |
| Current ratio | 1.62x | 1.08x | 1.32x | 1.51x | 1.48x | |
| Income quality | 1.57x | 1.86x | 1.57x | 2.19x | 1.80x | |
| Graham number | $27 | $20 | $18 | $12 | $14 | |
| Graham net-net | -$9 | -$9 | -$8 | -$8 | -$8 | |
| Tax burden | 85.3% | 81.2% | 80.3% | 61.2% | 96.7% | |
| Interest burden | 90.7% | 85.5% | 87.9% | 71.1% | 75.5% | |
| Working capital | $3.35B | $521.0M | $1.58B | $1.96B | $2.04B | |
| Invested capital | $33.16B | $28.04B | $25.27B | $23.61B | $22.84B | |
| Return on assets | 6.6% | 4.7% | 4.5% | 2.1% | 3.2% | |
| Operating ROA | 9.6% | 7.1% | 6.5% | 5.6% | 6.1% | |
| Return on tangible assets | 15.7% | 11.9% | 10.8% | 5.1% | 7.4% | |
| Return on equity | 11.9% | 8.5% | 8.3% | 4.0% | 6.3% | |
| Return on invested capital | 8.8% | 6.1% | 5.7% | 3.9% | 6.6% | |
| Return on capital employed | 10.4% | 8.0% | 7.2% | 6.4% | 6.9% | |
| Earnings yield | 2.0% | 1.4% | 1.9% | 1.1% | 1.7% | |
| Free cash flow yield | 2.6% | 2.0% | 2.0% | 1.4% | 2.2% | |
| Capex / Op. cash flow | 19.3% | 23.0% | 32.0% | 40.1% | 29.6% | |
| Capex / Depreciation | 64.0% | 62.3% | 66.9% | 53.9% | 50.7% | |
| Capex / Sales | 4.4% | 4.7% | 5.6% | 4.8% | 4.7% | |
| SG&A / Sales | 34.3% | 35.7% | 36.4% | 35.6% | 36.1% | |
| R&D / Sales | 10.2% | 9.6% | 9.9% | 10.4% | 10.1% | |
| Stock comp / Sales | 1.5% | 1.6% | 1.6% | 1.7% | 1.6% | |
| Intangibles / Total assets | 57.9% | 60.3% | 58.0% | 58.0% | 56.2% | |
| Days sales outstanding | 53d | 56d | 57d | 57d | 55d | |
| Days payables outstanding | 67d | 54d | 64d | 63d | 65d | |
| Operating cycle | 226d | 214d | 225d | 194d | 187d | |
| Cash conversion cycle | 159d | 160d | 161d | 131d | 122d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years